drugset / Trial / NCT00121862
Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite
Phase 2
Completed
60 enrolled
Access to Advanced Health Institute (AAHI)
Bill and Melinda Gates Foundation · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This study will evaluate the safety and immunogenicity of the Leish-111f + MPL-SE vaccine in adult subjects who have no evidence of previous exposure to the Leishmania parasite.
Timeline
- Start
- 2005-08
- Primary completion
- —
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leish-111f | Protein / enzyme biologic | 10 ug | — |
| Background | MPL-SE | Other / unclassified | 25 ug | — |